Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HRS2398 in Advanced Malignant Tumors
NCT05144061Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS2398 in cancer, sponsored by Hengrui Therapeutics. Primary endpoints: Dose-limiting toxicity up to 21 days, Maximum tolerated dose up to 6 months and 1 more. Started Dec 2021; status: completed.
02
Drugs
HRS2398
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05144061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05144061.